Ipsen Reports Robust Sales in the First Three Quarters of 2025 and Raises Full-Year Forecast

Written by Emily J. Thompson, Senior Investment Analyst

Source: Yahoo Finance

Updated: Oct 22 2025

0mins

Source: Yahoo Finance

Sales Growth: Ipsen reported a year-to-date total sales growth of 12.1% at constant exchange rates (CER) and 9.6% as reported, driven by strong performances in oncology, rare diseases, and neuroscience, particularly from products like Iqirvo®, Bylvay®, and Somatuline®.
Financial Guidance Upgrade: The company has upgraded its full-year 2025 financial guidance to reflect a total sales growth of around 10.0% at CER, with a core operating margin expected to be around 35.0% of total sales, based on better-than-expected performance and limited impact from generic competition on Somatuline®.
Acquisition Announcement: Ipsen announced the proposed acquisition of ImCheck Therapeutics, which includes a first-in-class Phase II asset aimed at expanding its oncology pipeline, with a focus on innovative immuno-oncology therapies.
Pipeline Developments: Recent updates include positive results from the Phase II LANTIC trial for a new long-acting aesthetic treatment, regulatory approvals for Bylvay® in Japan, and Cabometyx® in Europe for advanced neuroendocrine tumors, indicating ongoing advancements in Ipsen's therapeutic offerings.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.